NLRP3 and Alzheimer disease: The pharmacological inhibition of the NLRP3 inflammasome using OLT1177, an NLRP3 inhibitor, and VX−765, a caspase−1 inhibitor, significantly reduces IL−1β levels, thereby preventing microglial activation and memory deficits in AD mouse models [87,89].